RecruitingNot ApplicableNCT05945342

Development and Application of Comprehensive Intervention Techniques for Adolescent Depression

Research and Application of Key Technologies for Early Identification, Risk Warning and Comprehensive Intervention of Adolescent Depression


Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment

100 participants

Start Date

Jan 31, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

In order to realize the early identification, risk warning and comprehensive intervention of adolescent depression, this project carried out research on the diagnosis platform of adolescent depression, the construction of suicide risk warning and evaluation system, the development of interpersonal psychotherapy technology (IPT-A), and the rapid intervention technology of robotic navigation repetitive transcranial magnetic stimulation (rTMS). Through the extraction of psychological, peripheral and central biological characteristics of adolescent depression and the establishment of a diagnostic platform, combined with artificial neural network to achieve efficient and accurate identification of high risk of suicide population. Antidepressant drugs combined with psychotherapy and antidepressant drugs combined with rTMS physical therapy were used to improve the clinical effective rate and recovery rate. Finally, a comprehensive prevention and control technology suitable for hospitals, schools and families to participate in.


Eligibility

Min Age: 12 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is developing and testing a comprehensive intervention combining therapy, brain stimulation, and physical training for teenagers with depression. Researchers want to see if this multi-pronged approach can reduce depression symptoms more effectively than standard treatment. **You may be eligible if...** - You meet the diagnostic criteria for depression (DSM-5) without psychotic features - You scored at or above the required cutoffs on depression rating scales - You are having a first or recurring episode of depression and have not received antidepressants or formal psychotherapy in the past 2 months - You are right-handed and of Han Chinese ethnicity **You may NOT be eligible if...** - You have another mental health diagnosis (such as ADHD, autism, or intellectual disability) - You have an active infection, autoimmune disease, trauma, or are receiving hormone therapy - You have a history of brain injury or conditions affecting brain function - You are currently pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEREscitalopram combined with rTMS

The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication

DRUGEscitalopram combined with sham rTMS

The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication

DRUGEscitalopram

The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression

OTHERInterpersonal Psychotherapy for Adolescent

Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.

OTHEREscitalopram combined with psychotherapy

The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication


Locations(1)

The First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05945342


Related Trials